Guardant360® CDx FDA Approval Announcement
Home » Guardant360® CDx FDA Approval Announcement

GH AMEA on Social Media Guardant360® CDx FDA Approval Announcement
Guardant360® CDx FDA Approval Announcement
Guardant360® CDx FDA Approval Announcement
GH AMEA

Guardant360® CDx receiving FDA Approval is a landmark achievement for us. For advanced cancer patients in Asia, Middle East & Africa, this FDA approval lends even greater credibility to the test and its ability to provide comprehensive genomic profiling information that is critical to their cancer treatment. Click on the video to find out more:

View full press release at this link: https://lnkd.in/gwAmpCD

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.

Open chat
Message us